In recent years, the advent of immunotherapy, particularly immune checkpoint inhibitors targeting programmed cell death protein-1/programmed death-ligand 1 pathway, has provided a new therapeutic avenue for patients with advanced ESCC (4, 5, 20). This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.